Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | SVP and General Counsel | January 23, 2024 | January 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date January 23, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,691 |
Reported balance
After 2024-01-23 transaction · row 1
1 source rowRow 1 · 2024-01-23 · Grant · Acquired 3,639 · Balance 17,691 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $229.00 · Expires 2031-01-23 | Direct | 5,483 |
Reported balance
After 2024-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-23 · Grant · Acquired 5,483 · Balance 5,483 F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| Market Stock UnitSEC Table II · derivative / convertible security | Direct | 3,639 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Grant · Acquired 3,639 · Balance 3,639 F3: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. |
| Common StockSEC Table I · non-derivative | IndirectIn IRA | 530 |
Reported balance
Holding disclosure · report date 2024-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 530 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
F3: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2024 Filed Jan 25, 2024 20:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantMarket Stock Unit · Derivative | 3,639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007348 · ownership.xml · derivative · entry 4 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,639 Underlying: Common Stock · 3,639 shares Expires not disclosed F3 · derivative.exercise_price: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.exercise_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.expiration_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,483 | $0.00 Strike: $229.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007348 · ownership.xml · derivative · entry 3 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,483 Underlying: Common Stock · 5,483 shares Expires 2031-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 3,639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007348 · ownership.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,691 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 18:52 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Tax withholdingCommon Stock | 949 | $243.92 | $231,480.08 |
DisclosureSEC source: 0000950170-24-005304 · ownership.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,052 F1 · kind: Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · derivative · entry 10 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 800 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $227.33 | $227,330.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · nonDerivative · entry 6 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,001 Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 1,000 | $87.09 | $87,090.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · nonDerivative · entry 5 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · derivative · entry 9 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 1,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $73.75 | $0.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · derivative · entry 8 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 Underlying: Common Stock · 1,000 shares Expires 2032-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares issued pursuant to the exercise of this option represent 800 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $221.38 | $221,380.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · nonDerivative · entry 4 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,001 Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 800 | $215.73 | $172,584.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · nonDerivative · entry 3 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,001 Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 1,000 | $87.09 | $87,090.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · nonDerivative · entry 2 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 800 | $73.75 | $59,000.00 |
DisclosureSEC source: 0000950170-23-068575 · ownership.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All shares issued pursuant to the exercise of this option represent 800 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $73.75 | $0.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · derivative · entry 10 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 3,000 shares Expires 2032-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 7,000 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $206.73 | $206,730.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 7 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,001 Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $203.00 | $203,000.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 6 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,001 Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $204.00 | $204,000.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 5 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,001 Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 3,000 | $73.75 | $221,250.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 4 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $73.75 | $0.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · derivative · entry 9 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 4,000 shares Expires 2032-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 7,000 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,000 | $199.45 | $598,350.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 3 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,001 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.25 to $199.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $198.40 | $198,400.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 2 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,001 Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 4,000 | $73.75 | $295,000.00 |
DisclosureSEC source: 0000950170-23-067360 · ownership.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All shares issued pursuant to the exercise of the options reported herein represent 7,000 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 15,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002097 · doc4.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,001 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $91.79 | $0.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · derivative · entry 13 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 13,000 shares Expires 2030-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 13,000 shares underlying an overall option award of 32,000 shares. All exercised options had vested. As to the overall option for 32,000 shares, 25% of the shares underlying the option vested on March 5, 2021 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $287.86 | $28,786.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 11 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.86 to $287.86, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $286.62 | $114,648.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 10 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.61 to $286.63, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,038 | $285.74 | $582,338.12 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 9 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.50 to $286.29, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 829 | $285.15 | $236,389.35 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 8 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,538 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $284.50 to $285.49, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,549 | $283.85 | $439,683.65 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 7 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,367 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.42 to $284.21, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,628 | $282.97 | $743,645.16 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 6 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,916 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.41 to $283.33, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,656 | $281.97 | $748,912.32 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 5 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,544 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.32 to $282.30, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,800 | $280.66 | $505,188.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 4 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.22 to $281.16, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $279.10 | $111,640.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 3 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.06 to $279.38, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 600 | $277.91 | $166,746.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 2 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.90 to $277.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 14:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 13,000 | $91.79 | $1,193,270.00 |
DisclosureSEC source: 0000899243-23-001137 · doc4.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $91.79 | $0.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · derivative · entry 17 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 7,000 shares Expires 2030-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 7,000 shares underlying an overall option award of 32,000 shares. All exercised options had vested. As to the overall option for 32,000 shares, 25% of the shares underlying the option vested on March 5, 2021 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $283.61 | $56,722.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 15 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.22 to 284.00, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $281.79 | $56,358.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 14 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.45 to $282.14, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $280.41 | $56,082.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 13 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.17 to $280.66, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,100 | $279.46 | $307,406.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 12 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.00 to $279.95, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 361 | $277.77 | $100,274.97 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 11 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.51 to $278.13, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $276.40 | $27,640.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 10 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,061 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $275.24 | $27,524.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 9 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,161 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $274.70 | $109,880.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 8 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,261 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.24 to $275.04, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 539 | $273.48 | $147,405.72 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 7 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.19 to $273.95, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,500 | $272.74 | $409,110.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 6 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.18 to $273.14, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 800 | $271.27 | $217,016.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 5 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.87 to $271.85, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 700 | $270.25 | $189,175.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 4 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.72 to $270.69, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $268.99 | $80,697.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 3 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.64 to $269.54, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 500 | $267.88 | $133,940.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 2 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.32 to $268.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.